Taste Alterations in Cancer Patients Receiving Chemotherapy: A Neglected Side Effect?-猫眼课题宝

DOI：

10.1634/theoncologist.2009-0333

发表时间：

2010-08-01

期刊：

ONCOLOGIST

影响因子：

5.8

通讯作者：

中科院分区：

医学2区

文献类型：

作者：

Zabernigg, August;Gamper, Eva-Maria;Holzner, Bernhard

背景。在接受化疗 (CT) 的癌症患者中，味觉改变 (TA) 是一种常见但未被充分认识的治疗副作用。具有不同毒性特征的 CT 方案对 TA 的影响可能有所不同，但缺乏这方面的研究。本研究评估了 TA 的患病率及其与社会人口统计学和临床变量（尤其是 CT 方案）的关系。此外，还研究了 TA 与生活质量 (QOL) 之间的关联。患者和方法。纵向收集在库夫施泰因县医院内科接受 CT 治疗的 197 名癌症患者（肺癌，54.3%；胰腺癌，19.3%；结直肠癌，26.4%；年龄，65.2 +/- 10.4 岁；男性，57.4%）的 TA 和 QOL 数据，总共产生 1,024 次评估。患者完成了欧洲癌症研究与治疗组织 (EORTC) QLQ-C30 问卷以及从 EORTC 项目库中提取的两个有关 TA 的附加问题。使用混合效应模型进行统计分析。结果。研究表明，化疗患者中TA的患病率高得惊人（69.9%）。治疗组之间的 TA 评分存在明显差异：接受伊立替康的患者报告的 TA 显着高于其他治疗组的患者；接受吉西他滨和铂类药物联合治疗的患者报告的 TA 最低。此外，还发现 TA 与几个 QOL 维度之间存在显着关联，尤其是与食欲不振和疲劳有关。结论。 TA 的高患病率及其对 CT 患者生活质量的影响凸显了在研究和临床实践中迫切需要更多地关注这种副作用。肿瘤学家 2010；15：913-920

Background. Taste alterations (TAs) are a frequent but under-recognized treatment side effect in cancer patients undergoing chemotherapy (CT). CT regimens with different toxicity profiles may vary in their impact on TAs, but research on this topic is lacking. This study assesses the prevalence of TAs and their relation to sociodemographic and clinical variables, especially CT regimens. Furthermore, the association between TAs and quality of life (QOL) is investigated.Patients and Methods. TAs and QOL data were collected longitudinally in 197 cancer patients (lung cancer, 54.3%; pancreatic cancer, 19.3%; colorectal cancer, 26.4%; age, 65.2 +/- 10.4 years; male, 57.4%) who were receiving CT at the Department of Internal Medicine at Kufstein County Hospital, giving rise to a total of 1,024 assessment times. Patients completed the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire and two additional questions taken from the EORTC item bank concerning TAs. Statistical analyses were performed using mixed-effect models.Results. The study showed that the prevalence of TAs in chemotherapy patients is alarmingly high (69.9%). There were clear differences in TA scores among treatment groups: patients receiving irinotecan reported significantly more TAs than patients in other treatment groups; patients receiving a combination of gemcitabine and a platinum agent reported the lowest TAs. Additionally, significant associations between TAs and several QOL dimensions were found, especially with appetite loss and fatigue.Conclusion. The high prevalence of TAs and their impact on QOL in CT patients underscore the urgent need for increased attention to this side effect, both in research and in clinical practice. The Oncologist 2010;15: 913-920

Taste Alterations in Cancer Patients Receiving Chemotherapy: A Neglected Side Effect?

文献摘要

被引文献

相似文献